Medtronic plc’s Stock Price Soars to $85.25, Achieving a Robust 4.23% Increase

Medtronic plc (MDT)

85.25 USD +3.46 (+4.23%) Volume: 12.69M

Medtronic plc’s stock price soars to $85.25, marking a positive trading session with a significant increase of +4.23%. With a substantial trading volume of 12.69M, the medical technology company’s stock has seen a year-to-date growth of +6.72%, indicating a robust market performance.

Latest developments on Medtronic plc

Medtronic Plc (NYSE:MDT) has seen a surge in its stock price following the announcement of the Centers for Medicare & Medicaid Services (CMS) national coverage analysis for its Symplicity™ Spyral Renal Denervation System. The company’s shares rose as CMS started the Medicare coverage analysis for Medtronic’s renal denervation devices. Additionally, Medtronic broke above its 200-day moving average and achieved CE Mark approval for its BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a significant advancement in personalized care for Parkinson’s patients. The company also inked distribution deals with Contego and announced plans for tuck-in M&A. With these key events leading up to today, Medtronic’s stock price has seen a 4% increase, further solidifying its position in the market.

Medtronic plc on Smartkarma

Analysts on Smartkarma, such as Baptista Research, are optimistic about Medtronic Plc‘s performance following the company’s fiscal 2025 first-quarter results. The report highlights sustained growth in key financial metrics, with revenue up by 5.3% and exceeding guidance expectations. Medtronic’s Cardiovascular, Neuroscience, and Diabetes segments have made significant contributions to this positive performance, supported by strategic product innovations and global market expansions.

Baptista Research‘s analysis titled “Medtronic plc: Are Its Investments in Robotics with Hugo Robotic-Assisted Surgery System Yielding Results? – Major Drivers” sheds light on the company’s continued growth trajectory. The report emphasizes Medtronic’s strong performance across multiple business segments and its focus on driving innovation in the healthcare industry. With a bullish sentiment, analysts are optimistic about Medtronic’s investments in robotics and the potential for further growth in the future.

A look at Medtronic plc Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Medtronic Plc, a company that develops medical products, has received a positive overall outlook from Smartkarma Smart Scores. With high scores in Dividend and Resilience, the company is seen as stable and reliable for investors looking for long-term growth. While the scores for Value, Growth, and Momentum are not as high, the strong performance in Dividend and Resilience suggests that Medtronic Plc may be a good choice for those seeking steady returns over time.

Medtronic Plc‘s focus on therapeutic and diagnostic medical products has helped it earn a top score in Dividend, indicating that the company is committed to rewarding its shareholders. With a diverse product portfolio that includes offerings for various medical conditions, Medtronic Plc is positioned to weather market fluctuations, as reflected in its high Resilience score. While there may be room for improvement in Value, Growth, and Momentum, the company’s strong performance in Dividend and Resilience bodes well for its long-term outlook.

Summary: Medtronic, PLC develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma